Celera Genomics Group's goal of providing biological information surrounding genomic and gene sequences for drug discovery will require access to an enormous number of different cell and tissue types. The company plans to gain that access by forming partnerships with companies that seek to develop their own products based on those tissues.

In last week's deal with Geron Corp., for example, CRA (Rockville, Md.) will identify genes involved in early embryonic development through the analysis of GERN's pluripotent human stem cell lines.